Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06723366
Starting soon Not applicable

Protective Effect of Angong Niuhuang Against Negative Inflammatory Response and Neurologic Dysfunction After Cardiovascular Surgery

NCT06723366 · tracked via the Priya Life Science China tracker
Sponsor
Nanjing Medical University
Phase
Not applicable
Started
2025-01-01
Last updated
2024-12-12

Condition(s) studied

Cardio-pulmonary BypassCardiovascular SurgeryCerebral ProtectionBrain Injury

Investigational drug(s) / intervention(s)

Angong Niuhuang Pill (ANP) →Control (Standard treatment)

Angong Niuhuang Pill (ANP): Angong Niuhuang Pill (ANP) (3 g/pill, 1 pill/day for 5 days)

Control (Standard treatment): Blank control

Study summary

Neurologic Dysfunction is one of the main factors contributing to poor outcomes in cardiac surgery patients, except for heart failure. Atherosclerosis of the aorta, a history of cerebral infarction, and cervical artery disease are common clinical risk factors for cerebral neurological dysfunction after cardiac surgery. Results of preclinical studies suggested that Angong Niuhuang Pills (ANPs), a traditional Chinese patent medicine, including realgar, cinnabaris, Bovis Calculus, artificial Moschus, and powdered buffalo horn extract, decreased infarct volume and cerebral edema, and presented anti- atherosclerosis and cardio-protective effects in clinical and preclinical studies. The PANDA X trial is designed as a pilot study to explore the safety and efficacy of ANP in patients with moderate-to-severe neurologic dysfunction after cardiovascular surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * (1) an age \> 18 years, * (2) underwent cardiovascular surgery, * (3) diagnosis of acute neurologic dysfunction, including but not limited acute cerebral infarction of the internal carotid artery system, * (4) a National Institutes of Health Stroke Scale (NIHSS) score ranging from 10 to 20, * (5) a time from symptom onset to randomization within 36 h, * (6) provision of informed consent. Exclusion Criteria: * (1) not suitable for taking ANP after the dialectical process by a traditional Chinese medical doctor, * (2) received ANP within 1 month before stroke onset, * (3) liver failure, * (4) declined to participate in this study.

Primary outcome measure(s)

  • changes in the NIHSS score — after 14 days of randomization
    a National Institutes of Health Stroke Scale (NIHSS) score ranging from 10 to 20

Trial sites (2)

FacilityCityRegionStatus
Beijing Anzhen Hospital, Capital Medical University Beijing Beijing Municipality
The First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu

More Nanjing Medical University trials in China

Recurrent Liver Cancer: Reconceptualization and Reevaluation Recruiting
Exercise and Mindfulness Intervention for Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer Active, not recruiting
Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes Recruiting
Health Behavior Intervention for Colorectal Cancer Patients Starting soon
Effects and Mechanisms of Transcranial Direct Current Stimulation Combined With Dialectical Behavior Therapy Skills Training in Adults With Attention-Deficit/Hyperactivity Disorder Recruiting

Other trials for the same condition

Protective Effect of EECP Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery Starting soon
Prognostic Value of Neurometabolic Networks in CRC (PVNM-CRC) Recruiting
Discovery and Validation of Biomarkers for CSA-AKI Risk Prediction Recruiting
Exploring the Predictive Value of Electroencephalography Features in Perioperative Neurocognitive Disorders Following Cardiovascular Surgery Recruiting
The Study on the Efficacy of tDCS Stimulation of the Cerebellum Combined With XingNaoJing Injection in Patients With Consciousness Disorders After Cranial Injury Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06723366 on ClinicalTrials.gov ↗ ← All trials in China